Patents Assigned to Florida A&M University
  • Patent number: 9429943
    Abstract: Various examples are described for an artificial intelligence valet system. In one example, among others, a distributed information sharing system can obtain route information associated with a geographic area and provide the route information to a user vehicle in response to a request. In another example, an autonomous user vehicle can receive a request to autonomously proceed to a user defined location; obtain route information; and determine a route to the user defined location using the route information. In another example, a collision avoidance system can determine if an object is in a path of travel of a vehicle based at least in part upon sensory data and maneuver the vehicle based at least in part upon an object determination. In another example, an accident reporting system can determine an occurrence of a violation of a vehicle; obtain recordings of the environment surrounding the vehicle; and report the violation.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: August 30, 2016
    Assignee: FLORIDA A&M UNIVERSITY
    Inventors: Sihle K. Wilson, Ronald E. Benson
  • Patent number: 9193711
    Abstract: Novel compounds for the treatment of estrogen receptor-mediated disorders, including breast cancer, and methods of treatment using the novel compounds. The novel compounds, when administered in a safe and effective amount, present extended binding to estrogen receptors in breast tissue without activating the estrogen receptors. Estrogen is blocked from binding to the estrogen receptors for an extended period of time, effectively hindering growth of breast cancer cells.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 24, 2015
    Assignee: Florida A&M University
    Inventor: John S. Cooperwood
  • Publication number: 20150237871
    Abstract: The fungus Metarhizum anisopliae and the fungus Beauveria bassiana have been found to be effective for control of small hive beetles in honey bee colonies. The control of small hive beetles in honey bee colonies is effected by applying to the beetle, the honey bee hive, the vicinity of the honey bee hive, or the surrounding soils, or the soil in the pan at the hive bottom board, a composition of a miticidally effective amount of Metarhizum anisopliae or Beauveria bassiana.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Applicant: FLORIDA A&M UNIVERSITY
    Inventor: Lambert Houssou Ble KANGA
  • Patent number: 9051381
    Abstract: Isolated disease-related genes from muscadine (Vitis rotundifolia) and Florida hybrid bunch grape (Vitis spp.) grapes, and complementary DNA associated therewith. The cDNA can be utilized in small RNA technologies to promote expression of disease tolerance-related genes to induce production of disease-tolerance related gene products for resisting disease occurrence in Florida hybrid bunch and V. vinifera. The genes include, but are not limited to, stilbene synthase, chalcone synthase, chitinase, PR 4, PR 10, ?-1, 3-glucanase, peroxidase, and a subunit of Oxygen-Evolving Enhancer Protein 1. These genes were found to enhance tolerance of Florida hybrid bunch and muscadine grape to a plurality of pathogenic diseases, including, for example, Pierce's disease and anthracnose.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: June 9, 2015
    Assignee: Florida A&M University
    Inventors: Mehboob B. Sheikh, Devaiah Kambiranda, Hemanth KN. Vasanthaiah
  • Patent number: 8889713
    Abstract: The compounds herein disclosed are N-substituted tetrahydroisoquinoline benzamide and benzene sulfonamide compounds that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-substituted tetrahydroisoquinoline compounds have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6- to 10-fold less than the IC50 of Tamoxifen.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 18, 2014
    Assignee: Florida A&M University
    Inventors: Kinfe Ken Redda, Madhavi Gangapuram
  • Patent number: 8865206
    Abstract: Dermal delivery is best suited for the various skin diseases or disorders. However, the stratum corneum limits the permeation of number of suitable pharmaceutical agents for dermal delivery. Certain embodiments of the present invention include surface modified multilayered nanostructures. The modification was completed by using fatty acids enabling delivery of a significant amount of one or more pharmaceutical agent(s) into deeper layers of the epidermis and dermis to treat skin diseases or disorders. Each active pharmaceutical agent can be encapsulated into the separate layers of the nanostructures.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 21, 2014
    Assignee: Florida A&M University
    Inventors: Mandip Sachdeva, Punit Shah
  • Patent number: 8703798
    Abstract: An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring; the 10 position is N—R10, O, S, S?O, CH2, or C?O, where R10 is a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring. In one embodiment the quarternary N-5 atom is —CH3 and the 10 position is N—(CH2)5-Ph.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: April 22, 2014
    Assignee: Florida A&M University
    Inventor: Seth Y. Ablordeppey
  • Publication number: 20140073656
    Abstract: Novel compounds for the treatment of estrogen receptor-mediated disorders, including breast cancer, and methods of treatment using the novel compounds. The novel compounds, when administered in a safe and effective amount, present extended binding to estrogen receptors in breast tissue without activating the estrogen receptors. Estrogen is blocked from binding to the estrogen receptors for an extended period of time, effectively hindering growth of breast cancer cells.
    Type: Application
    Filed: October 10, 2013
    Publication date: March 13, 2014
    Applicant: Florida A&M University
    Inventor: John S. Cooperwood
  • Patent number: 8647661
    Abstract: Dermal delivery is best suited for the various skin diseases or disorders. However, the stratum corneum limits the permeation of number of suitable pharmaceutical agents for dermal delivery. Certain embodiments of the present invention include surface modified multilayered nanostructures. The modification was completed by using fatty acids enabling delivery of a significant amount of one or more pharmaceutical agent(s) into deeper layers of the epidermis and dermis to treat skin diseases or disorders. Each active pharmaceutical agent can be encapsulated into the separate layers of the nanostructures.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 11, 2014
    Assignee: Florida A&M University
    Inventors: Mandip Sachdeva, Punit Shah
  • Patent number: 8546426
    Abstract: The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 1, 2013
    Assignee: Florida A&M University Board of Trustees
    Inventors: Kinfe Ken Redda, Madhavi Gangapuram
  • Publication number: 20130231824
    Abstract: Various examples are described for an artificial intelligence valet system. In one example, among others, a distributed information sharing system can obtain route information associated with a geographic area and provide the route information to a user vehicle in response to a request. In another example, an autonomous user vehicle can receive a request to autonomously proceed to a user defined location; obtain route information; and determine a route to the user defined location using the route information. In another example, a collision avoidance system can determine if an object is in a path of travel of a vehicle based at least in part upon sensory data and maneuver the vehicle based at least in part upon an object determination. In another example, an accident reporting system can determine an occurrence of a violation of a vehicle; obtain recordings of the environment surrounding the vehicle; and report the violation.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 5, 2013
    Applicant: FLORIDA A&M UNIVERSITY
    Inventors: Sihle K. Wilson, Ronald E. Benson
  • Patent number: 8476303
    Abstract: The compounds herein disclosed are N-aminopyrrolylmethyltetrahydropyridine analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-aminopyrrolylmethyltetrahydropyridines have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 2, 2013
    Assignee: Florida A&M University Board of Trustees
    Inventors: Kinfe Ken Redda, Madhavi Gangapuram
  • Publication number: 20130109716
    Abstract: The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.
    Type: Application
    Filed: November 30, 2011
    Publication date: May 2, 2013
    Applicant: Florida A&M University Board of Trustees
    Inventors: Kinfe Ken Redda, Madhavi Gangapuram
  • Publication number: 20130109724
    Abstract: The compounds herein disclosed are N-aminopyrrolylmethyltetrahydropyridine analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-aminopyrrolylmethyltetrahydropyridines have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.
    Type: Application
    Filed: November 30, 2011
    Publication date: May 2, 2013
    Applicant: Florida A&M University Board of Trustees
    Inventors: Kinfe Ken Redda, Madhavi Gangapuram
  • Patent number: 8403172
    Abstract: A collapsible straw assembly. A first component includes a beverage container having a recess formed therein. A second component includes a collapsible straw having a collapsed configuration and expanded configuration. The straw is disposed in the recess when in collapsed configuration and is ready for use in expanded configuration. A third component includes a protective liner disposed in overlying relation to the straw in collapsed configuration. The liner has an outer surface containing protective materials and an inner surface containing sanitizing materials. Adhesives may be disposed on the surface of the recess and on the inner surface of the liner. When in the collapsed configuration, the inner end of the straw can be attached to the container, and the outer end of the straw can be attached to the liner. This allows simultaneous expansion of the straw when the liner is removed to expose the straw.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: March 26, 2013
    Assignee: Florida A&M University
    Inventors: Malcom Kelley, Nordian Brown, Leitoya Snelling
  • Patent number: 8367121
    Abstract: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, ?-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O2.
    Type: Grant
    Filed: February 6, 2010
    Date of Patent: February 5, 2013
    Assignee: Florida A & M University
    Inventors: Elizabeth Anne Mazzio, Karam F Soliman
  • Patent number: 8314143
    Abstract: A compound, pharmaceutical composition and method for the treatment of mammals wherein the active therapeutic agent is a compound having the structure: wherein: R1 is an electronegative substituent, R2 is R1 or alkyl, R3 is H or O-alkyl, R4 and R5 are the same or different and are alkyl and R6 is H or OH.
    Type: Grant
    Filed: December 31, 2007
    Date of Patent: November 20, 2012
    Assignee: Florida A&M University
    Inventors: Kinfe Redda, Chavonda Janeebra Mills, Nelly Mateeva
  • Publication number: 20120157493
    Abstract: “An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring; the 10 position is N—R10, O, S, S?O, CH2, or C?O, where R10 is a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring. In one embodiment the quarternary N-5 atom is —CH3 and the 10 position is N—(CH2)5-Ph.
    Type: Application
    Filed: February 24, 2012
    Publication date: June 21, 2012
    Applicant: FLORIDA A&M UNIVERSITY
    Inventor: Seth Y. Ablordeppey
  • Patent number: 7700587
    Abstract: Haloperidol analogs that conforms to the structural formulae: wherein: R is H, or —(CH2)n—OH, n is an integer from 0 to 2, and A is a heterocyclic bridging group, consisting essentially of carbon and at least one nitrogen atom, which effectively maintains the distance between the moieties connected thereby such that the compound (1) is incapable of metabolizing to BCPP+ like species, (2) has an affinity for the D2 receptor subtype of 15<D2<250 and (3) functions as a dopamine receptor antagonist, or the structural formulae: wherein: R1 is H, or —(CH2)n—OH, n is an integer from 0 to 2, B is an aza- or diaza-bicyclo group, which effectively maintains the distance between the moieties connected thereby such that the compound is incapable of metabolizing to BCPP+ like species; and Z is —CH— or N; and pharmaceutically acceptable salts, esters, derivatives, metal complexes, conjugates and prodrugs thereof.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: April 20, 2010
    Assignee: Florida A&M University
    Inventors: Seth Y. Ablordeppey, Donald M. N. Sikazwe